Tadeusz Robak

机构：Copernicus Memorial Hospital, Medical University of Lodz, Children's Specialized Hospital · ORCID：0000-0002-3411-6357

发表论文 1217 篇 · 总被引 38070 次 · h-index 81

代表论文

• Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL (2025 · Blood · 被引 40)
• Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results (2025 · Journal of Clinical Oncology · 被引 25)
• The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs (2025 · Journal of Clinical Medicine · 被引 4)
• Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial (2025 · The Lancet Haematology · 被引 4)
• A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type (2025 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 4)
• Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk (2025 · Acta Haematologica Polonica · 被引 4)